Therapy (dsDNA damage)

Initial cohort (n = 69)
18 Patients with PD

5 TP53 and CHK2 wt
PD patients with low ATM levels

1 PD patient with mutations in CHK2

12 PD patients with mutations in TP53

Apoptosis  Growth arrest  Senescence

Validation cohort (n = 109)
10 Patients with PD

4 TP53 and CHK2 wt
PD patients with low ATM levels

2* PD patient with mutations in CHK2

4 TP53 and CHK2 wt
PD patients with low ATM levels

5* PD patients with mutations in TP53

\* 1 patient with both TP53 and CHK2 mutation

B

ATM mRNA level cut-off (lower % of cohort)

p-value

Cohort 1  Cohort 2